Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Cash & Equivalents (2019 - 2025)

Pulmonx has reported Cash & Equivalents over the past 7 years, most recently at $69.8 million for Q4 2025.

  • Quarterly Cash & Equivalents fell 1.63% to $69.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $69.8 million through Dec 2025, down 1.63% year-over-year, with the annual reading at $69.8 million for FY2025, 1.63% down from the prior year.
  • Cash & Equivalents was $69.8 million for Q4 2025 at Pulmonx, down from $76.5 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $209.3 million in Q1 2021 and troughed at $63.3 million in Q3 2024.
  • The 5-year median for Cash & Equivalents is $98.3 million (2023), against an average of $108.2 million.
  • Year-over-year, Cash & Equivalents skyrocketed 1188.61% in 2021 and then plummeted 40.24% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $148.5 million in 2021, then crashed by 31.48% to $101.7 million in 2022, then fell by 17.88% to $83.5 million in 2023, then decreased by 15.13% to $70.9 million in 2024, then fell by 1.63% to $69.8 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Cash & Equivalents are $69.8 million (Q4 2025), $76.5 million (Q3 2025), and $75.5 million (Q2 2025).